Get the Stockscreener App
4.00
3.61%
-0.15
After Hours:
4.02
0.02
+0.50%
Aquestive Therapeutics Inc stock is traded at $4.00, with a volume of 881.11K.
It is down -3.61% in the last 24 hours and up +23.08% over the past month.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
See More
Previous Close:
$4.15
Open:
$4.16
24h Volume:
881.11K
Relative Volume:
0.60
Market Cap:
$397.31M
Revenue:
$58.36M
Net Income/Loss:
$-25.72M
P/E Ratio:
-10.99
EPS:
-0.3641
Net Cash Flow:
$-24.91M
1W Performance:
-5.44%
1M Performance:
+23.08%
6M Performance:
+27.39%
1Y Performance:
+4.71%
1-Day Range:
$3.95
$4.17
1-Week Range:
$3.95
$4.3199
52-Week Range:
$2.12
$5.80
Aquestive Therapeutics Inc Stock (AQST) Company Profile
Name
Aquestive Therapeutics Inc
Sector
Phone
908-941-1900
Address
30 TECHNOLOGY DRIVE, WARREN, NJ
Compare AQST with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AQST
Aquestive Therapeutics Inc
|
4.00 | 412.21M | 58.36M | -25.72M | -24.91M | -0.3641 |
|
ZTS
Zoetis Inc
|
150.75 | 67.73B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.31 | 45.73B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.70 | 44.38B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.51 | 18.97B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
298.14 | 13.73B | 2.99B | 1.21B | 1.13B | 25.06 |
Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| Dec-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-10-24 | Initiated | Leerink Partners | Outperform |
| Apr-11-24 | Initiated | Piper Sandler | Overweight |
| Mar-28-24 | Initiated | Raymond James | Outperform |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Apr-22-19 | Initiated | H.C. Wainwright | Buy |
| Jan-03-19 | Initiated | Lake Street | Buy |
| Aug-20-18 | Initiated | JMP Securities | Mkt Outperform |
| Aug-20-18 | Initiated | RBC Capital Mkts | Outperform |
View All
Aquestive Therapeutics Inc Stock (AQST) Latest News
Is Aquestive Therapeutics Inc. a growth stock or a value stockSmart Portfolio Recommendation For Beginners - jammulinksnews.com
What makes Aquestive Therapeutics Inc. stock price move sharplyBreakout Stocks Tips For Beginners - jammulinksnews.com
How does Aquestive Therapeutics Inc. generate profit in a changing economyOutperformance with explosive growth - jammulinksnews.com
Should I hold or sell Aquestive Therapeutics Inc. stock in 2025Maximize gains with strategic stock entries - jammulinksnews.com
What are the latest earnings results for Aquestive Therapeutics Inc.Rapid market gains - jammulinksnews.com
What are the technical indicators suggesting about Aquestive Therapeutics Inc.Unprecedented profit potential - jammulinksnews.com
What institutional investors are buying Aquestive Therapeutics Inc. stockRemarkably fast returns - jammulinksnews.com
How Efficient Is Aquestive Therapeutics Inc. at Controlling Operating CostsBreakout Confirmation Tool - Metal.it
What is the dividend policy of Aquestive Therapeutics Inc. stockUnlock powerful portfolio optimization tools - jammulinksnews.com
How strong is Aquestive Therapeutics Inc. company’s balance sheetAccelerated investment success - jammulinksnews.com
Why Aquestive Therapeutics Inc. stock attracts strong analyst attentionFree VIP Group - Metal.it
Is Aquestive Therapeutics Inc. a good long term investmentExceptional stock performance - PrintWeekIndia
What drives Aquestive Therapeutics Inc. stock priceDynamic growth stocks - PrintWeekIndia
What analysts say about Aquestive Therapeutics Inc. stock outlookTremendous gains - jammulinksnews.com
Why Aquestive Therapeutics Inc. stock is on top investor watchlistsDynamic capital growth - jammulinksnews.com
Should I buy Aquestive Therapeutics Inc. stock before earningsRapidly growing investment returns - jammulinksnews.com
Aquestive Therapeutics Inc. Stock Analysis and ForecastBreakthrough investment results - PrintWeekIndia
What analysts say about Aquestive Therapeutics Inc. stockAccelerated profit realization - jammulinksnews.com
Aquestive Therapeutics Names Sherry Korczynski as Chief Commercial Officer - GlobeNewswire
EpiPen Veteran to Lead Aquestive's Revolutionary Oral Epinephrine Launch as New Chief Commercial Officer - Stock Titan
After Leaping 29% Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Are Not Flying Under The Radar - simplywall.st
Aquestive's Anaphylm to be reviewed by Health Canada - MSN
Aquestive Therapeutics Inc Stock (AQST) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.71%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):